CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

How Data Science is Revolutionizing Genomics

How Data Science is Revolutionizing...

Human-specific Proteins Uncovered by Exploring Genetic Uncharted Territory

Human-specific Proteins Uncovered by...

A Broader Perspective of Genomics

A Broader Perspective of Genomics

The Future Of Genomics In Theory-Focused Approaches

The Future Of Genomics In...

Role of Human Genomic Data in Future

Role of Human Genomic Data in Future

Essentiality of Single-cell Genomics Technology

Essentiality of Single-cell Genomics...

Tactics to Handle Genomic Data

Tactics to Handle Genomic Data

Benefits of Advanced Genomic Testing

Benefits of Advanced Genomic Testing

How Data Science is Revolutionizing Genomics

How Data Science is Revolutionizing...

Human-specific Proteins Uncovered by Exploring Genetic Uncharted Territory

Human-specific Proteins Uncovered by...

A Broader Perspective of Genomics

A Broader Perspective of Genomics

The Future Of Genomics In Theory-Focused Approaches

The Future Of Genomics In...

Role of Human Genomic Data in Future

Role of Human Genomic Data in Future

Essentiality of Single-cell Genomics Technology

Essentiality of Single-cell Genomics...

Tactics to Handle Genomic Data

Tactics to Handle Genomic Data

Benefits of Advanced Genomic Testing

Benefits of Advanced Genomic Testing

Scopus BioPharma Makes New Management Appointment Following the Acquisition of Chief Immunotherapy Firm

Life Sciences Review Life Sciences Review | Wednesday, January 12, 2022
Tweet

Olimmune’s President and Chief Executive, Alan Horsager, Ph.D., has been named President of Scopus, with responsibility for supervising the company’s rapidly developing immuno-oncology portfolio.


FREMONT, CA: Scopus BioPharma, a clinical-stage biopharmaceutical company, developing transformational therapeutics for serious diseases with substantial unmet medical needs, recently announced a new management appointment following its acquisition of Olimmune, a leading immunotherapy company. Olimmune’s President and Chief Executive, Alan Horsager, Ph.D., has been named President of Scopus, with responsibility for supervising the company’s rapidly developing immuno-oncology portfolio.


Joshua R. Lamstein, Chairman of Scopus, stated, “We are excited to add Dr. Horsager to Scopus leadership team. Dr. Horsager has an impressive background as both a scientist and biotech entrepreneur. The combination of the immuno-oncology assets of Scopus and Olimmune creates one of the leading global portfolios of bifunctional STAT3 inhibitors for the treatment of multiple cancers. We have great confidence in Dr. Horsagers ability to integrate these assets into a single, seamless pipeline.”


Dr. Horsager previously worked at Cal State LA as the Director of LA BioSpace, the university’s endeavor to foster the formation of bioscience ventures in the Los Angeles area. 


Dr. Horsager formerly co-founded and led two biotechnology companies and served as a Research Assistant Professor at the University of Southern California. Dr. Horsager earned his B.A. and Ph.D. in Neuroscience from the University of Washington and the University of Southern California, respectively.


Dr. Horsager stated, “The combined immuno-oncology portfolio is comprised of STAT3siRNA, STAT3ASO and STAT3decoy. These assets are comprehensive and highly complementary. Inhibiting STAT3 is frequently characterized as the holy grail of treating and curing cancer. Overseeing the integration and development of these assets is an extraordinary opportunity.”


“Large pharmaceutical companies, venture capitalists and the capital markets are placing premium valuations on companies with promising programs targeting STAT3. Our approach, highly cell-selective STAT3 inhibition combined with TLR9 immunostimulation, is highly distinguishable with compelling advantages over other approaches. We believe Dr. Horsager will play an important role in increasing awareness of our competitive advantages and unique value proposition. This, we believe, will drive a significant near-term increase in shareholder value,” added Lamstein.


Weekly Brief

loading
Top 10 Genomics Solutions Companies in Europe/UK – 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/scopus-biopharma-makes-new-management-appointment-following-the-acquisition-of-chief-immunotherapy-firm--nwid-470.html